1/2 REPRIEVE Extension for Trial Completion

1/2 REPRIEVE 延期以完成试验

基本信息

  • 批准号:
    10479464
  • 负责人:
  • 金额:
    $ 656.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary-Abstract Globally, cardiovascular disease (CVD) burden is increasing and a major cause of mortality among people with HIV (PWH). However, data are not yet available from large trials on an effective primary CVD prevention strategy for PWH. The ongoing REPRIEVE trial will address this critical knowledge gap, hypothesizing that statin therapy, with pleiotropic effects on LDL, immune activation and inflammatory pathways, will modify traditional and nontraditional risks and prevent major adverse cardiovascular events (MACE) in PWH. REPRIEVE is well-positioned to provide high quality, clinically actionable and generalizable information to shift the current paradigm of HIV care, in alignment with the goals of NHLBI and OAR to reduce CVD and improve the overall health of PWH. REPRIEVE has met major challenges, anticipated for a large trial. 7,770 participants (31% female, 43% Black, 25% Latino) were enrolled from over 100 sites in 12 countries, a diverse, generalizable population. Retention is high, >90%. Endpoint (MACE) are accumulating steadily despite a low median ASCVD risk score of 4.5%, consistent with the hypothesis that nontraditional risks contribute to CVD in HIV. The Mechanistic Substudy has met its goal, enrolling over 800 participants for serial coronary CT angiography (CTA) and immune function. Preliminary baseline data from the substudy support our hypothesis, linking plaque to CVD risk but also independently to IL-6 and Lp-PLA2, key indices of immune function and arterial inflammation that are being targeted in REPRIEVE. Moreover, REPRIEVE is being leveraged to assess statin effects on COVID severity, and long-term effects in PWH, critical unanswered questions for the field. REPRIEVE has executed well over 6 years and is fundamentally strong. However, with a long duration of recruitment and protocol revisions to identify the optimal at-risk group given new guidelines, median duration of follow up is still short at 3.5 years. REPRIEVE needs additional time, projected at 2 years, plus a close out year, to collect necessary MACE to ensure adequate power, analyze, and disseminate this data. The pressing need for data from a large global primary prevention trial has only grown since REPRIEVE was initiated. Completion of the trial will protect the value of the initial NIH investment and honor the commitment to our participants and scientific community to meet the Aims of the trial. This application for the Clinical Coordinating Center (CCC) of the REPRIEVE Extension for Trial Completion focuses on the clinical rationale and coordination of the trial. The Data Coordinating Center (DCC) application focuses on data management, including the coronary CTA data of the Mechanistic Substudy, and the statistical rationale for the trial design.
项目摘要-摘要 在全球范围内,心血管疾病(CVD)的负担正在增加,并且是心血管疾病患者死亡的主要原因。 艾滋病毒(PWH)。然而,关于有效的一级心血管疾病预防的大型试验数据尚未获得 威尔斯亲王医院的策略。正在进行的REPRIEVE试验将解决这一关键的知识差距,假设 他汀类药物治疗对低密度脂蛋白、免疫激活和炎症通路具有多效性, 传统和非传统风险,并预防PWH的主要不良心血管事件(MACE)。 REPRIEVE定位良好,可提供高质量、临床可操作和可推广的信息, 目前的艾滋病毒护理模式,与NHLBI和OAR的目标保持一致,以减少CVD和改善 威尔斯亲王医院的整体健康状况。REPRIEVE遇到了重大挑战,预计将进行大规模审判。7,770 参与者(31%女性,43%黑人,25%拉丁美洲人)来自12个国家的100多个地点, 可推广的人口。保留率高,> 90%。终点(MACE)尽管较低,但仍在稳步累积 ASCVD风险评分中位数为4.5%,与非传统风险导致CVD的假设一致, 艾滋病。机械子研究达到了其目标,招募了800多名参与者进行连续冠状动脉CT 血管造影(CTA)和免疫功能。子研究的初步基线数据支持我们的假设, 将斑块与CVD风险联系起来,但也独立于IL-6和Lp-PLA 2,免疫功能的关键指标, 动脉炎症是REPRIEVE的目标。此外,还利用REPRIEVE来评估 他汀类药物对COVID严重程度的影响,以及对PWH的长期影响,这是该领域尚未回答的关键问题。 REPRIEVE已经执行了6年多,基本上是强大的。然而,随着时间的推移, 招募和方案修订,以确定最佳的风险组,考虑到新的指南, 随访时间仍然较短,为3.5年。保留需要额外的时间,预计为2年,加上关闭 收集必要的MACE,以确保足够的功率,分析和传播这些数据。按压 自REPRIEVE启动以来,对大型全球一级预防试验数据的需求不断增长。 试验的完成将保护NIH最初投资的价值,并荣誉对我们的承诺。 参与者和科学界,以满足试验的目的。本申请为临床协调 试验完成延期中心(CCC)重点关注临床依据, 协调审判。数据协调中心(DCC)应用程序侧重于数据管理, 包括机制子研究的冠状动脉CTA数据和试验设计的统计学依据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pamela Susan Douglas其他文献

Pamela Susan Douglas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pamela Susan Douglas', 18)}}的其他基金

Clinical and Molecular Epidemiology of High Risk Coronary Plaque
高危冠状动脉斑块的临床和分子流行病学
  • 批准号:
    10219348
  • 财政年份:
    2019
  • 资助金额:
    $ 656.79万
  • 项目类别:
Clinical and Molecular Epidemiology of High Risk Coronary Plaque
高危冠状动脉斑块的临床和分子流行病学
  • 批准号:
    10459303
  • 财政年份:
    2019
  • 资助金额:
    $ 656.79万
  • 项目类别:
Clinical and Molecular Epidemiology of High Risk Coronary Plaque
高危冠状动脉斑块的临床和分子流行病学
  • 批准号:
    9817023
  • 财政年份:
    2019
  • 资助金额:
    $ 656.79万
  • 项目类别:
REPRIEVE - CCC - Lead Application
REPRIEVE - CCC - 主要应用
  • 批准号:
    10400795
  • 财政年份:
    2014
  • 资助金额:
    $ 656.79万
  • 项目类别:
REPRIEVE - CCC - Lead Application
REPRIEVE - CCC - 主导应用
  • 批准号:
    8730843
  • 财政年份:
    2014
  • 资助金额:
    $ 656.79万
  • 项目类别:
REPRIEVE - CCC - Lead Application
REPRIEVE - CCC - 主导应用
  • 批准号:
    8909176
  • 财政年份:
    2014
  • 资助金额:
    $ 656.79万
  • 项目类别:
Data Concepts and Terminology Standards in Cardiovascular Imaging
心血管成像中的数据概念和术语标准
  • 批准号:
    8514314
  • 财政年份:
    2012
  • 资助金额:
    $ 656.79万
  • 项目类别:
PROMISE Trial: Clinical Coordinating Center
PROMISE 试验:临床协调中心
  • 批准号:
    8153243
  • 财政年份:
    2009
  • 资助金额:
    $ 656.79万
  • 项目类别:
PROMISE Trial: Clinical Coordinating Center
PROMISE 试验:临床协调中心
  • 批准号:
    7768791
  • 财政年份:
    2009
  • 资助金额:
    $ 656.79万
  • 项目类别:
PROMISE Trial: Clinical Coordinating Center
PROMISE 试验:临床协调中心
  • 批准号:
    8529018
  • 财政年份:
    2009
  • 资助金额:
    $ 656.79万
  • 项目类别:

相似海外基金

ImproviNg rEnal outcomes following coronary angiograPhy and/or percuTaneoUs coroNary intErventions: a pragmatic, adaptive, patient-oriented randomized controlled trial
改善冠状动脉造影和/或经皮冠状动脉介入治疗后的肾脏结局:一项务实、适应性、以患者为导向的随机对照试验
  • 批准号:
    478732
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Operating Grants
SBIR Phase II: Novel size-changing, gadolinium-free contrast agent for magnetic resonance angiography
SBIR II 期:用于磁共振血管造影的新型尺寸变化、无钆造影剂
  • 批准号:
    2322379
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Cooperative Agreement
Neonatal Optical Coherence Tomography Angiography to Assess the Effects of Postnatal Exposures on Retinal Development and Predict Neurodevelopmental Outcomes
新生儿光学相干断层扫描血管造影评估产后暴露对视网膜发育的影响并预测神经发育结果
  • 批准号:
    10588086
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
Motion-Resistant Background Subtraction Angiography with Deep Learning: Real-Time, Edge Hardware Implementation and Product Development
具有深度学习的抗运动背景减影血管造影:实时、边缘硬件实施和产品开发
  • 批准号:
    10602275
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
Highly Accelerated Magnetic Resonance Angiography using Deep Learning
使用深度学习的高加速磁共振血管造影
  • 批准号:
    2886357
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Studentship
Development of a method to simultaneously obtain cerebral blood flow information and progression of cerebral white matter lesions using head MR angiography.
开发一种使用头部磁共振血管造影同时获取脑血流信息和脑白质病变进展的方法。
  • 批准号:
    23K14839
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a new diagnostic method for coronary artery disease using automated image analysis with postmortem coronary angiography CT
使用死后冠状动脉造影 CT 自动图像分析开发冠状动脉疾病的新诊断方法
  • 批准号:
    23K19795
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Novel ultrahigh speed swept source OCT angiography methods in diabetic retinopathy
糖尿病视网膜病变的新型超高速扫源 OCT 血管造影方法
  • 批准号:
    10656644
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
Automated Machine Learning-Based Brain Artery Segmentation, Anatomical Prior Labeling, and Feature Extraction on MR Angiography
基于自动机器学习的脑动脉分割、解剖先验标记和 MR 血管造影特征提取
  • 批准号:
    10759721
  • 财政年份:
    2023
  • 资助金额:
    $ 656.79万
  • 项目类别:
SCH: A physics-informed machine learning approach to dynamic blood flow analysis from static subtraction computed tomographic angiography imaging
SCH:一种基于物理的机器学习方法,用于从静态减影计算机断层血管造影成像中进行动态血流分析
  • 批准号:
    2205265
  • 财政年份:
    2022
  • 资助金额:
    $ 656.79万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了